[SCHEDULE 13G/A] Beam Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

FMR LLC (Fidelity) and Abigail P. Johnson have filed a Schedule 13G disclosing passive ownership of 8,979,673 shares of AdaptHealth Corp. (AHCO) common stock, representing 6.7 % of the shares outstanding as of 30 Jun 2025.

The filing indicates:

• Sole voting power: 8,976,041 shares
• Sole dispositive power: 8,979,673 shares
• No shared voting or dispositive power

FMR is classified as a parent holding company / control person under Rule 13d-1(b)(1)(ii)(G) and certifies the stake is held in the ordinary course of business with no intent to influence control. A related Exhibit 99 lists the relevant subsidiaries.

The disclosure confirms that one of the world’s largest asset managers now owns a >5 % position in AHCO, potentially boosting market visibility and liquidity while adding an influential, yet passive, shareholder to the register.

Positive

• High-quality institutional sponsorship: Fidelity’s 6.7 % stake may enhance confidence among other investors and improve liquidity.
• Sole voting and dispositive control: FMR can support management on key ballots, potentially stabilizing governance outcomes.

Negative

• None.

Insights

Equity Portfolio Manager

TL;DR: Fidelity discloses 6.7 % passive stake, adding blue-chip support but no control intentions.

This 13G signals a meaningful vote of confidence from a top-tier institutional investor. Fidelity’s nearly 9 million-share position could enhance trading liquidity and broaden analyst coverage. Because the filing is on Schedule 13G—rather than 13D—it confirms a passive stance, so no activism catalyst is implied. Still, Fidelity’s resources and governance standards usually bode well for issuer oversight. Impact is moderately positive, primarily reputational.

Corporate Governance Analyst

TL;DR: Large passive holder lowers free float, modestly shifts voting dynamics, overall neutral to positive.

With sole voting rights on 6.7 % of shares, FMR becomes a key blockholder. While the firm disclaims control ambitions, its votes can influence routine matters such as director elections or say-on-pay. The concentration slightly reduces free float but also places shares in stable hands. No red flags emerge; certification affirms ordinary-course purchase. Market should view the development as low-risk and marginally favorable.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 9)

BEAM THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

07373V105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 07373V105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 15,073,316.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,083,498.08
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,083,498.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 07373V105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,083,498.08
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,083,498.08

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

15.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BEAM THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 26 Landsdowne Street,Cambridge,MA,US,02139
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 07373V105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15083498.08
(b)	Percent of class: 15.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 15083498.08
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BEAM THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of BEAM THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many AdaptHealth (AHCO) shares does Fidelity now own?

8,979,673 shares, equal to 6.7 % of the outstanding common stock.

Does Fidelity intend to influence control of AdaptHealth?

No. The Schedule 13G filing certifies the stake is passive and held in the ordinary course of business.

What voting power does FMR LLC hold in AHCO?

FMR reports 8,976,041 shares with sole voting power and 0 shared voting power.

Why was a Schedule 13G filed instead of a Schedule 13D?

13G is used for passive holders exceeding the 5 % threshold, whereas 13D is for investors seeking control or active influence.

Who signed the filing on behalf of FMR and Abigail P. Johnson?

Authorized signatory Richard Bourgelas signed under a power of attorney dated 23 May 2023.